News and publications
Publications
Below is a list of select publications co-authored by Deep Apple founders and/or scientists that describe the science underlying Deep Apple’s approach to drug discovery.
Docking for EP4R antagonists active against inflammatory pain
(Nature Communications, 06 December 2023)
Time-resolved cryo-EM of G protein activation by a GPCR
(bioRxiv preprint, 21 March 2023)
Insights into distinct signaling profiles of the µOR activated by diverse agonists
(Nature Chemical Biology, 21 November 2022)
Structure determination of inactive-state GPCRs with a universal nanobody
(Nature Structural & Molecular Biology, 17 November 2022)
Structure-based discovery of nonopioid analgesics acting through the α2A-adrenergic receptor
(Science, 30 September 2022)
Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity
(Nature, 28 September 2022)
Ultra-large library docking for discovering new chemotypes
(Nature, 06 February 2019)
Apple Tree Partners Unveils Deep Apple Therapeutics to Dramatically Accelerate Drug Discovery with Structure-Based, Ultra-Large Library Virtual Screening and Deep Learning Models
SAN FRANCISCO and NEW YORK, December 14, 2023/PR Newswire/ – Apple Tree Partners (ATP), a leader in life sciences venture capital, today announced $52 million in Series A funding for its portfolio company Deep Apple Therapeutics, created and incubated by ATP to rapidly discover novel small molecule therapeutics for high-value targets through virtual screening of AI-generated virtual libraries.